Biology Reference
In-Depth Information
[69]
Fried, P., Watkinson, B., James, D., Gray, R. (2002). Current and former marijuana use:
preliminary findings of a longitudinal study of effects on IQ in young adults.
Cmaj
,
166, 887-891.
[70]
Fukudome, Y., Ohno-Shosaku, T., Matsui, M., Omori, Y., Fukaya, M., Tsubokawa, H.,
Taketo, M.M., Watanabe, M., Manabe, T., Kano, M. (2004). Two distinct classes of
muscarinic action on hippocampal inhibitory synapses: M2-mediated direct suppression
and M1/M3-mediated indirect suppression through endocannabinoid signalling.
Eur J
Neurosci
, 19, 2682-2692.
[71]
Gebremedhin, D., Lange, A.R., Campbell, W.B., Hillard, C.J., Harder, D.R. (1999).
Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type
Ca2+ channel current.
Am J Physiol
, 276, H2085-2093.
[72]
Gerard, C.M., Mollereau, C., Vassart, G., Parmentier, M. (1991). Molecular cloning of
a human cannabinoid receptor which is also expressed in testis.
Biochem J
, 279, 129-
134.
[73]
Gerdeman, G., Lovinger, D.M. (2001). CB1 cannabinoid receptor inhibits synaptic
release of glutamate in rat dorsolateral striatum.
J Neurophysiol
, 85, 468-471.
[74]
Gerdeman, G.L., Ronesi, J., Lovinger, D.M. (2002). Postsynaptic endocannabinoid
release is critical to long-term depression in the striatum.
Nat Neurosci
, 5, 446-451.
[75]
Giuffrida, A., Beltramo, M., Piomelli, D. (2001). Mechanisms of endocannabinoid
inactivation: biochemistry and pharmacology.
J Pharmacol Exp Ther
, 298, 7-14.
[76]
Giuffrida, A., Parsons, L.H., Kerr, T.M., Rodriguez de Fonseca, F., Navarro, M.,
Piomelli, D. (1999). Dopamine activation of endogenous cannabinoid signaling in
dorsal striatum.
Nat Neurosci
, 2, 358-363.
[77]
Glaser, S.T., Abumrad, N.A., Fatade, F., Kaczocha, M., Studholme, K.M., Deutsch,
D.G. (2003). Evidence against the presence of an anandamide transporter.
Proc Natl
Acad Sci U S A
, 100, 4269-4274.
[78]
Gong, J.P., Onaivi, E.S., Ishiguro, H., Liu, Q.R., Tagliaferro, P.A., Brusco, A., Uhl,
G.R. (2006). Cannabinoid CB2 receptors: immunohistochemical localization in rat
brain.
Brain Res
, 1071, 10-23.
[79]
Gonzalez, S., Scorticati, C., Garcia-Arencibia, M., de Miguel, R., Ramos, J.A.,
Fernandez-Ruiz, J. (2006). Effects of rimonabant, a selective cannabinoid CB1 receptor
antagonist, in a rat model of Parkinson's disease.
Brain Res
, 1073-1074, 209-219.
[80]
Goparaju, S.K., Ueda, N., Yamaguchi, H., Yamamoto, S. (1998). Anandamide
amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor
ligand.
FEBS Lett
, 422, 69-73.
[81]
Gulyas, A.I., Cravatt, B.F., Bracey, M.H., Dinh, T.P., Piomelli, D., Boscia, F., Freund,
T.F. (2004). Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and
postsynaptic compartments in the rat hippocampus, cerebellum and amygdala.
Eur J
Neurosci
, 20, 441-458.
[82]
Haj-Dahmane, S., Shen, R.Y. (2005). The wake-promoting peptide orexin-B inhibits
glutamatergic transmission to dorsal raphe nucleus serotonin neurons through
retrograde endocannabinoid signaling.
J Neurosci
, 25, 896-905.
[83]
Hajos, N., Katona, I., Naiem, S.S., MacKie, K., Ledent, C., Mody, I., Freund, T.F.
(2000). Cannabinoids inhibit hippocampal GABAergic transmission and network
oscillations.
Eur J Neurosci
, 12, 3239-3249.
